Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 7/20 | 0.40 |
| ▸ | KDM5A | P29375 | 7/20 | 0.40 |
| ▸ | ASPH | Q12797 | 5/20 | 0.38 |
| ▸ | KDM8 | Q8N371 | 5/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ADH1B | P00325 | 1/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
| ▸ | ADH7 | P40394 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 6/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1970944 | 0.84 | ATR (0.40) | KDM4ESMN1; SMN2TSHR | |
| SCHEMBL21354949 | 0.79 | ADH1B (0.37) | LMNAADH1BADH1CADH1AADH7 | |
| SCHEMBL15527764 | 0.76 | GABRP (0.45) | KDM4CKDM5AASPHKDM8KDM4E | |
| SCHEMBL21355260 | 0.70 | KLKB1 (0.35) | ADH1BADH1CADH1AADH7 | |
| SCHEMBL21355297 | 0.70 | ADH1B (0.35) | ADH1BADH1CADH1AADH7 | |
| SCHEMBL1128728 | 0.70 | ADH1B (0.36) | ADH1BADH1CADH1AADH7 | |
| SCHEMBL4857487 | 0.69 | ADH1B (0.41) | SMN1; SMN2ADH1BADH1CADH1AADH7 | |
| SCHEMBL83616 | 0.69 | SMN1; SMN2 (0.59) | KDM4CKDM5AASPHKDM8KDM4E | |
| SCHEMBL29486104 | 0.69 | SMN1; SMN2 (0.59) | KDM4CKDM5AASPHKDM8KDM4E | |
| SCHEMBL19857453 | 0.68 | KDM4E (0.60) | KDM4CKDM5AASPHKDM8KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293763-B2 | 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents | GENENTECH, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| EP-2231662-B1 | 8-ANILINOIMIDAZOPYRIDINES AND THEIR USE AS ANTI-CANCER AND/OR ANTI-INFLAMMATORY AGENTS | GENENTECH INC (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20100280063-A1 | 8-ANILINOIMIDAZOPYRIDINES AND THEIR USE AS ANTI-CANCER AND/OR ANTI-INFLAMMATORY AGENTS | GENENTECH, INC. | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280063-A1 | 8-ANILINOIMIDAZOPYRIDINES AND THEIR USE AS ANTI-CANCER AND/OR ANTI-INFLAMMATORY AGENTS | MAP3K8, MAPK8, MAP3K1 | KDM4C 1454/4885KDM5A 763/4885ASPH 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.